Monitor upcoming Phase 1b trial initiation in progressive supranuclear palsy and watch for further clinical data that could validate ARV-102's efficacy in neurodegenerative diseases.
Price Chart
Executive Summary
Arvinas announced positive Phase 1 clinical trial data for ARV-102, showing greater than 50% degradation of LRRK2 in cerebrospinal fluid of Parkinson's disease patients, with the drug well-tolerated across all doses. The company plans to initiate a Phase 1b trial in progressive supranuclear palsy in Q2 2026, with potential for a registrational trial in late 2026.
Key Facts
- ARV-102 demonstrated >50% LRRK2 degradation in CSF at all doses by day 14, maintained through day 28
- Multiple oral doses of ARV-102 (20mg, 40mg, 80mg) were well tolerated with no serious adverse events
- Data presented at AD/PD 2026 conference in Copenhagen
- Company plans to initiate Phase 1b trial in progressive supranuclear palsy in Q2 2026
- Potential to initiate a registrational trial in late 2026
Financial Impact
No immediate financial impact, but positive clinical data increases the probability of future revenue from ARV-102
Risk Factors
- Phase 1 success does not guarantee success in later-stage trials
- Regulatory approval is still pending and not guaranteed
- Competitors may have similar therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-019026 |
| Document: arv-102datapresentationp.htm | 0001628280-26-019026 |
| Document: 0001628280-26-019026-index-headers.html | 0001628280-26-019026 |
| Document: 0001628280-26-019026.txt | 0001628280-26-019026 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | 144 | $9.08 $8.26 | ▼ −9.03% | ▼ −7.91% | $7.41 (−18.39%) |
Jun 22, 2026 14w ago | 8-K | $8.14 $8.29 | ▲ +1.84% | ▲ +0.83% | $7.41 (−8.97%) |
Jun 2, 2026 17w ago | 8-K | $7.70 $6.98 | ▲ +9.35% | ▲ +5.53% | $7.41 (+3.77%) |
May 12, 2026 20w ago | 8-K | $9.57 $8.78 | ▼ −8.26% | ▼ −8.33% | $7.41 (−22.57%) |
May 12, 2026 20w ago | 8-K | $9.57 $8.78 | ▼ −8.26% | ▼ −8.33% | $7.41 (−22.57%) |
May 12, 2026 20w ago | Press Release | $9.57 $8.78 | ▲ +8.26% | ▲ +8.33% | $7.41 (+22.57%) |
May 8, 2026 20w ago | 144 | $9.66 $8.78 | ▼ −9.11% | ▼ −9.02% | $7.41 (−23.29%) |
May 8, 2026 20w ago | 144 | $9.66 $8.78 | ▼ −9.11% | ▼ −9.02% | $7.41 (−23.29%) |
May 5, 2026 21w ago | Press Release | $10.61 $9.57 | ▲ +9.80% | ▲ +11.79% | $7.41 (+30.16%) |
May 1, 2026 22w ago | 8-K | $10.51 $10.19 | ▼ −3.04% | ▼ −5.39% | $7.41 (−29.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access